Literature DB >> 8070518

Complement C1q does not bind monomeric beta-amyloid.

S W Snyder1, G T Wang, L Barrett, U S Ladror, D Casuto, C M Lee, G A Krafft, R B Holzman, T F Holzman.   

Abstract

The tendency of both labeled and unlabeled beta-amyloid to bind in solution to C1q, the recognition species in the complement cascade, was examined using both hydrodynamic and spectroscopic methods. Potential binding interactions were evaluated using a purified synthetic beta-amyloid 1-40 sequence, alone, and selectively labeled at the amino terminus with spectroscopic probes. The probes permitted both absorbance and fluorescence analyses of beta-amyloid binding interactions. Under conditions used for the analyses beta-amyloid exists exclusively as a monomer in solution, and C1q retains an intact quaternary structure and is capable of binding to IgM. When mixed together the monomeric beta-amyloid does not bind to, or interact with, the complement C1q at concentrations below approximately 100 microM. The data suggest that if beta-amyloid toxicity is associated with complement activation in Alzheimer's disease then monomeric beta-amyloid is likely not responsible for activation through the classical complement pathway.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8070518     DOI: 10.1006/exnr.1994.1121

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  7 in total

1.  Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner.

Authors:  L Bergamaschini; S Canziani; B Bottasso; M Cugno; P Braidotti; A Agostoni
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

Review 2.  The significance of neuroinflammation in understanding Alzheimer's disease.

Authors:  P Eikelenboom; R Veerhuis; W Scheper; A J M Rozemuller; W A van Gool; J J M Hoozemans
Journal:  J Neural Transm (Vienna)       Date:  2006-10-13       Impact factor: 3.575

3.  Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease.

Authors:  S E Stoltzner; T J Grenfell; C Mori; K E Wisniewski; T M Wisniewski; D J Selkoe; C A Lemere
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

Review 4.  Complement in the brain.

Authors:  Robert Veerhuis; Henrietta M Nielsen; Andrea J Tenner
Journal:  Mol Immunol       Date:  2011-05-04       Impact factor: 4.407

Review 5.  Neuroinflammatory processes in Alzheimer's disease.

Authors:  Michael T Heneka; M Kerry O'Banion; Dick Terwel; Markus Peter Kummer
Journal:  J Neural Transm (Vienna)       Date:  2010-07-15       Impact factor: 3.575

6.  Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice.

Authors:  Qiaoqiao Shi; Saba Chowdhury; Rong Ma; Kevin X Le; Soyon Hong; Barbara J Caldarone; Beth Stevens; Cynthia A Lemere
Journal:  Sci Transl Med       Date:  2017-05-31       Impact factor: 17.956

Review 7.  Contribution of Neurons and Glial Cells to Complement-Mediated Synapse Removal during Development, Aging and in Alzheimer's Disease.

Authors:  Celia Luchena; Jone Zuazo-Ibarra; Elena Alberdi; Carlos Matute; Estibaliz Capetillo-Zarate
Journal:  Mediators Inflamm       Date:  2018-11-11       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.